eFFECTOR Therapeutics has started dosing patients in the Phase ll expansion portion of its ongoing Phase l/ll study of eFT508 for the treatment of relapsed, refractory, non-germinal centre B cell (non-GCB) diffuse large B-cell lymphoma (DLBCL).

In this portion, patients will be given a 200mg dose of eFT508 twice daily, which was established in the Phase l dose-escalation portion of the trial.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Phase l/ll trial is an open-label, sequential-group, dose-escalation and cohort-expansion study designed to analyse the safety, pharmacokinetics, pharmacodynamics and anti-tumour activity of eFT508 in patients with haematological malignancies.

The primary objective of the expansion cohort is the objective response rate (ORR) of eFT508 in non-GCB DLBCL patients.

eFFECTOR Therapeutics president and CEO Steve Worland said: “This Phase ll expansion cohort builds on our Phase l results, where we observed a confirmed partial response in one of two non-GCB DLBCL patients enrolled during dose escalation.

“Patients with non-GCB DLBCL who have failed other available treatment options face a devastating disease.”

“Patients with non-GCB DLBCL who have failed other available treatment options face a devastating disease.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Non-GCB DLBCL is an aggressive form of non-Hodgkin’s lymphoma (NHL) that is partly caused by the activation of nuclear factor kappa-light-chain-enhancer of activated B-cells (NFkB) and frequently responds poorly to standard treatments.

According to the Lymphoma Research Foundation, DLBCL is estimated to account for 30% of the newly diagnosed NHL cases each year.

eFT508, an oral, small molecule inhibitor of MNK1/2, has previously secured orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of DLBCL.